(Q26830287)

3

0 references

Gordon C. Jayson

object named as

G Jayson

6

0 references

author name string

M Hall

1

1 reference

C Gourley

2

1 reference

J Ledermann

4

1 reference

M Gore

5

1 reference

G Rustin

8

1 reference

S Kaye

9

1 reference

full work available at URL

language of work or name

1 reference

5 February 2013

11 references

13 March 2019

14 March 2019

24 March 2019

3 April 2019

19 June 2019

25 June 2019

5 November 2020

13 November 2020

7 April 2021

13 January 2024

http://eprints.whiterose.ac.uk/100588/

content deliverer

White Rose Research Online

copyright license

Creative Commons Attribution-NonCommercial-ShareAlike 3.0 Unported

0 references

published in

British Journal of Cancer

12 references

13 March 2019

14 March 2019

24 March 2019

3 April 2019

19 June 2019

25 June 2019

29 May 2020

5 November 2020

13 November 2020

7 April 2021

13 January 2024

108

1 reference

issue

2

1 reference

page(s)

250-8

1 reference

Creative Commons Attribution-NonCommercial-ShareAlike 3.0 Unported

copyright license

11 references

13 March 2019

14 March 2019

24 March 2019

3 April 2019

19 June 2019

25 June 2019

29 May 2020

5 November 2020

13 November 2020

7 April 2021

on focus list of Wikimedia project

13 January 2024

copyright status

copyrighted

0 references

ScienceSource

0 references

cites work

Angiogenesis inhibitors for the treatment of ovarian cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3566823

Diversity of function is inherent in matricellular proteins: an appraisal of thrombospondin 1

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3566823

A phase I/II dose-escalation trial of bevacizumab in previously treated metastatic breast cancer

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3566823

Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3566823

Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3566823

Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3566823

The efficacy and safety of bevacizumab beyond first progression in patients treated with first-line mFOLFOX6 followed by second-line FOLFIRI in advanced colorectal cancer: a multicenter, single-arm, phase II trial (CCOG-0801).

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3566823

OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3566823

A phase 3 trial of bevacizumab in ovarian cancer

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3566823

Trastuzumab treatment in multiple lines: current data and future directions

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3566823

Adverse events risk associated with bevacizumab addition to breast cancer chemotherapy: a meta-analysis

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3566823

From chemotherapy to targeted therapy in adjuvant treatment for stage III colon cancer

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3566823

Clinical trials of vascular disrupting agents in advanced non--small-cell lung cancer.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3566823

Efficacy of trabectedin in platinum-sensitive-relapsed ovarian cancer: new data from the randomized OVA-301 study

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3566823

Addition of bevacizumab to weekly paclitaxel significantly improves progression-free survival in heavily pretreated recurrent epithelial ovarian cancer

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3566823

Phase II trial of combretastatin A4 phosphate, carboplatin, and paclitaxel in patients with platinum-resistant ovarian cancer.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3566823

Using bevacizumab to treat metastatic cancer: UK consensus guidelines

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3566823

Disease course patterns after discontinuation of bevacizumab: pooled analysis of randomized phase III trials

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3566823

Activity of sorafenib in recurrent ovarian cancer and primary peritoneal carcinomatosis: a gynecologic oncology group trial

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3566823

Which factors predict bowel complications in patients with recurrent epithelial ovarian cancer being treated with bevacizumab?

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3566823

Potent preclinical impact of metronomic low-dose oral topotecan combined with the antiangiogenic drug pazopanib for the treatment of ovarian cancer

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3566823

Bridging the gap between cytotoxic and biologic therapy with metronomic topotecan and pazopanib in ovarian cancer.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3566823

Intraperitoneal VEGF inhibition using bevacizumab: a potential approach for the symptomatic treatment of malignant ascites?

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3566823

When 'never-events' occur despite adherence to clinical guidelines: the case of venous thromboembolism in clear cell cancer of the ovary compared with other epithelial histologic subtypes.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3566823

Effect of bevacizumab in older patients with metastatic colorectal cancer: pooled analysis of four randomized studies.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3566823

Cediranib, an oral inhibitor of vascular endothelial growth factor receptor kinases, is an active drug in recurrent epithelial ovarian, fallopian tube, and peritoneal cancer

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3566823

Sustained progression-free survival with weekly paclitaxel and bevacizumab in recurrent ovarian cancer

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3566823

The risk of gastrointestinal perforation and/or fistula in patients with recurrent ovarian cancer receiving bevacizumab compared to standard chemotherapy: a retrospective cohort study

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3566823

Pathophysiologic effects of vascular-targeting agents and the implications for combination with conventional therapies.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3566823

Antiangiogenic therapy for cancer: current and emerging concepts

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3566823

Antiangiogenic concentrations of paclitaxel induce an increase in microtubule dynamics in endothelial cells but not in cancer cells

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3566823

5,6-Dimethylxanthenone-4-acetic acid (DMXAA), a novel antivascular agent: phase I clinical and pharmacokinetic study

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3566823

Redefining the target: chemotherapeutics as antiangiogenics

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3566823

A phase II study of sunitinib in patients with recurrent epithelial ovarian and primary peritoneal carcinoma: an NCIC Clinical Trials Group Study.

28 September 2017

1 reference

https://api.crossref.org/works/10.1038%2FBJC.2012.541

Incorporation of bevacizumab in the primary treatment of ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBJC.2012.541

Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBJC.2012.541

A Phase II, open-label study evaluating pazopanib in patients with recurrent ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBJC.2012.541

Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: a trial of the California, Chicago, and Princess Margaret Hospital phase II consortia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBJC.2012.541

Bevacizumab in Combination With Oxaliplatin, Fluorouracil, and Leucovorin (FOLFOX4) for Previously Treated Metastatic Colorectal Cancer: Results From the Eastern Cooperative Oncology Group Study E3200

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBJC.2012.541

Big costs for little gain in ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBJC.2012.541

Venous thromboembolic events with chemotherapy plus bevacizumab: a pooled analysis of patients in randomized phase II and III studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBJC.2012.541

Safety of bevacizumab in metastatic breast cancer patients undergoing surgery.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBJC.2012.541

Gastrointestinal perforation associated with bevacizumab use in metastatic colorectal cancer: results from a large treatment observational cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBJC.2012.541

Prospective evaluations of continuous weekly paclitaxel regimen in recurrent platinum-resistant epithelial ovarian cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBJC.2012.541

Randomized phase II placebo-controlled trial of maintenance therapy using the oral triple angiokinase inhibitor BIBF 1120 after chemotherapy for relapsed ovarian cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBJC.2012.541

Weekly paclitaxel as a single agent or in combination with carboplatin or weekly topotecan in patients with resistant ovarian cancer: the CARTAXHY randomized phase II trial from Groupe d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens (GI

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBJC.2012.541

Incidence and management of bevacizumab-associated gastrointestinal perforations in patients with recurrent ovarian carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBJC.2012.541

Paclitaxel chemotherapy and vascular toxicity as assessed by flow-mediated and nitrate-mediated vasodilatation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBJC.2012.541

Incidence and predictors of venous thromboembolism (VTE) among ambulatory high-risk cancer patients undergoing chemotherapy in the United States.

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3566823

Randomized, double-blind, placebo-controlled phase II study of AMG 386 combined with weekly paclitaxel in patients with recurrent ovarian cancer

28 November 2018

1 reference

12 December 2020

The microtubule-affecting drug paclitaxel has antiangiogenic activity

1 reference

12 December 2020

What is the risk of bowel perforation associated with bevacizumab therapy in ovarian cancer?

1 reference

12 December 2020

Bevacizumab plus cyclophosphamide in heavily pretreated patients with recurrent ovarian cancer

1 reference

12 December 2020

Bevacizumab beyond first progression is associated with prolonged overall survival in metastatic colorectal cancer: results from a large observational cohort study (BRiTE)

1 reference

12 December 2020

Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial

1 reference

12 December 2020

Bevacizumab with peri-operative epirubicin, cisplatin and capecitabine (ECX) in localised gastro-oesophageal adenocarcinoma: a safety report

1 reference

https://api.crossref.org/works/10.1038%2FBJC.2012.541

7 January 2021

inferred from DOI database lookup

Identifiers

DOI

10.1038/BJC.2012.541

1 reference

Dimensions Publication ID

0 references

0 references

1041239039

0 references

1959242

1 reference

1 reference

1959242

PubMed publication ID

23385789

1 reference